Boston Scientific Corporation $BSX Shares Acquired by L & S Advisors Inc

L & S Advisors Inc boosted its position in Boston Scientific Corporation (NYSE:BSX) by 13.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,090 shares of the medical equipment provider’s stock after purchasing an additional 8,525 shares during the period. L & S Advisors Inc’s holdings in Boston Scientific were worth $7,743,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. 1248 Management LLC acquired a new position in shares of Boston Scientific in the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific during the first quarter valued at $27,000. Sound Income Strategies LLC boosted its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Princeton Global Asset Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific during the 2nd quarter worth about $37,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Wells Fargo & Company raised their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Leerink Partners raised their target price on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Trading Up 0.8%

Shares of NYSE BSX opened at $104.99 on Friday. The business has a 50 day simple moving average of $99.81 and a 200 day simple moving average of $102.56. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The stock has a market cap of $155.65 billion, a price-to-earnings ratio of 56.15, a PEG ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 over the last three months. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.